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Abstract
Background: Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) play a major role in
the maintenance of extracellular matrix homeostasis and are involved in the process of tumour
invasion and metastasis in several malignant tumour entities. The goal of this study is to evaluate
the diagnostic value of various circulating MMPs and TIMPs in blood plasma for a non-invasive
detection of transitional cell carcinoma of the bladder (TCC).
Methods: In this study the concentrations of MMP1, MMP2, MMP3, MMP9, their inhibitors TIMP1,
TIMP2, and the MMP1/TIMP1-complex (MTC1) were quantified in blood plasma with the sandwich
enzyme-linked immunosorbent assay (ELISA). Blood plasma samples were investigated from 68
patients (non-metastasized, n = 57 and metastasized, n = 11) with TCC of the bladder and from 79
healthy controls. The mROC program was used to calculate the best two- and three- marker
combinations. The diagnostic values for all single markers and the marker combinations were
estimated both by the overall diagnostic performance index area under the ROC curve (AUC) and
the sensitivity and specificity at cutoff limits with the highest diagnostic accuracy and at the 90% and
95% limits of sensitivity and specificity, respectively.
Results: The median MMP2 concentration was elevated in blood plasma in all patient groups with
TCC in comparison to the controls (p < 0.001). The concentrations of TIMP1, TIMP2, and MTC1
in plasma probes were significantly lower from patients with non-metastasized TCC compared to
the controls. MMP2 tested alone reached the highest sensitivity and specificity at 75%, respectively.
The sensitivity and specificity increased when tested in combination with MMP9 and TIMP1 (97%,
94%, respectively). The combination of MMP9 and TIMP1 also showed an improved sensitivity
(80%) and specificity (99%) than tested alone.
Conclusion: MMP2 is a statistically significant marker in blood plasma for bladder cancer detection
with an increased diagnostic value in combination with MMP9 and TIMP1. This study showed that
the highest sensitivities and specificities are not obtained by testing each marker alone. As shown
by the best two-marker combination, which includes MMP9 and TIMP1, the optimized combination
does not always include the best single markers.
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Background
The transitional cell carcinoma (TCC) of the bladder is the
second most common malignancy of all genitourinary
tumours after prostate cancer. For the year 2006 the Amer-
ican Cancer Society published an estimated number of
approximately 61,420 new cases of bladder cancer in men
and of 44,690 new cases in women. According to the
American Cancer Society approximately 13,060 men and
8,990 women will die from TCC of the bladder in 2006 in
the United States [1]. Hematuria and dysuria are often the
only symptoms at an early stage of bladder cancer. Ultra-
sound, urine analysis, urine cytology, and cystoscopy are
currently the most common diagnostic tools. Urine cytol-
ogy is the "gold standard" for a non-invasive diagnosis,
but has a low sensitivity of less then 30% [2]. Cystoscopy
with biopsy is an invasive diagnostic method of TCC with
so far the highest sensitivity and specificity, >90% respec-
tively [2]. Therefore, it is a compelling task to find a more
sensitive and specific non-invasive marker for the early
diagnosis of TCC and early detection of recurrences [2-5].
Voided urine is easy and inexpensive to obtain and could
be used routinely in clinical practice to look for bladder
tumour markers [6,7]. Although voided urine would be
ideal for screening, follow-up efforts have been made for
bladder tumour detection in blood serum [8,9].
One of the essential alterations that occur in malignancy
is tissue invasion and metastasis [10]. Degradation of the
basement membrane and the extracellular matrix (ECM)
is a prerequisite for tumour invasion. Matrix metallopro-
teinases (MMPs) belong to the group of ECM degradation
enzymes. The balance of secreted MMPs and their specific
inhibitors (TIMPs) plays an important role in maintaining
connective tissue homeostasis in normal tissue [11]. In
neoplastic diseases an imbalance of MMPs and TIMPs,
leading to an excess of degradative activity, is supposed to
be linked to the invasive character of tumour cells [12,13].
MMPs are divided according to their target protein into
several families [14]. In this study we will focus on MMPs,
which are described in the literature to have an impact in
bladder tumour carcinogenesis: the collagenase MMP1
[15], the stromelysin MMP3 [15], and the gelatinases
MMP2 [4] and MMP9 [7,16]. Endogenous proteins
known as tissue inhibitors of metalloproteinase (TIMPs)
also regulate activities of MMPs [17]. Activated MMP1,
MMP3, and latent forms of MMP2 and MMP9 bind to and
are inhibited by TIMP1 and TIMP2. Some studies have
shown that TIMP1 binds preferably to MMP9 and TIMP2
to MMP2 [18,19].
Studies concerning the expression of MMPs in TCC of the
bladder are rare. Few analyzes of MMPs have been con-
ducted in blood serum [20]. Since MMPs and TIMPs are
released from platelets and leukocytes into serum during
blood collections [21] plasma should be used to deter-
mine circulating MMPs and TIMPs [22,23]. To our knowl-
edge there are no data available yet, which determine
MMPs, TIMPs, and MMP1/TIMP1-complex (MTC1) in
blood plasma as non-invasive tumour markers for TCC.
This study is performed to investigate the impact of
MMP1, MMP2, MMP3, MMP9, TIMP1, TIMP2, and MTC1
in blood plasma for non-invasive diagnosis of TCC of the
bladder.
Methods
Patients
A total of 68 patients with TCC of the bladder were
included in our study. The study followed the tenets of the
Declaration of Helsinki. Our local Medical Ethical Com-
mittee (Chairman: Prof. R. Uebelhack, Charite University
Hospital, Berlin, Germany) approved the study protocol
"Detection of metalloproteinases in patients with geni-
tourinary cancer" on July 16th, 2002. From each patient a
verbal informed consent was obtained. The tumour was
diagnosed by biopsy or obtained by transurethral resec-
tion of the bladder (TURB) or radical cystectomy and cat-
egorized according to the TNM-classification [24].
Patients were excluded from this study with other diseases
or conditions, which are known from the literature to
result in an increase of MMPs, e.g. renal cell carcinoma
[25], prostate cancer [22], liver diseases [26], rheumatoid
diseases [27]. For further staging patients were diagnosed
by abdominal ultrasound, intravenous pyelography, com-
puter tomography, magnetic resonance imaging, and/or
bone scans additionally to the histopathologically
obtained diagnosis. Fifty-seven patients (45 male, 12
female; median age, 68 years, range 42–86 years) with
TCC of the bladder (Ta, n = 32; T1/pT1, n = 11; pT2, n =
6; pT3, n = 4; pT4, n = 4; G1, n = 20; G2, n = 23; G3, n =
14) were included in this study without evidence of
metastasis. Eleven patients (9 male, 2 female; median age:
61 years, range 39–72) were included in the study suffer-
ing from TCC of the bladder (pT2, n = 5; pT3, n = 4; pT4,
n = 2) with metastasis. Lymph node metastasis (N1: n = 8;
N2: n = 2) was found in 10 patients and organ metastasis
in 2 patients.
Control group
The control group consisted of 40 female (median age: 39
years, range 23–69 years) and 39 male (median age: 48
years, range 20–78 years) healthy volunteers without any
history of cancer, inflammatory or immunodeficiency dis-
eases and were tested during the same period.
Laboratory blood tests were performed to determine liver
enzymes, prostate specific antigen (PSA), white blood
cells, and C-reactive protein. Urinalysis was performed to
evaluate urinary infections or kidney diseases. VolunteersBMC Urology 2006, 6:19 http://www.biomedcentral.com/1471-2490/6/19
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with pathological test results were excluded from the
study.
Blood samples
Blood samples were obtained from each patient by
venous puncture into lithium-heparin coated blood col-
lection tubes ("monovettes", No. 03.1528, 03.1589 by
Sarstedt GmbH, Nuembrecht, Germany) before the begin-
ning of therapy. The blood collection tubes were stored at
room temperature (22°C) for 30 min and then centri-
fuged (1600 × g) at 4°C for 15 min. The supernatant was
carefully removed and stored at -80°C until further
processing. Samples were thawed at room temperature
just prior to the assays.
Measurement of MMP- and TIMP-concentrations in blood 
plasma
Plasma MMP- and TIMP-concentrations were measured
by using the sandwich ELISA technique as reported previ-
ously in detail from our laboratory [28]. We used the com-
mercially available quantitative sandwich ELISA test kits
(Amersham International, Little Chalfont, U.K.; article no.
RPN 2610, RPN 2617, RPN 2613, RPN 2614, RPN 2611,
RPN 2618, RPN 2612) for the determination of MMP1,
MMP2, MMP3, MMP9, TIMP1, TIMP2, and MTC1 con-
centrations in the blood plasma of the patients and the
control group. With these ELISA techniques the non-
active forms (proforms) of MMPs and in case of MTC1 the
complex of MMP1 and TIMP1 were measured. The probes
were diluted with assay buffers (MMP1 1:5, MMP2 1:51,
MMP3 1:1, MMP9 1:11, TIMP1 1:101, TIMP2 1:4, and
MTC1 1:11). The measurements were conducted accord-
ing to the manufactures guidelines. The cubic-spline
method was used for calculation of concentrations (EIA/
KIN-star-program, Fa. WEPAH-MED, Berlin, Germany)
from the absorbances measured on a microplate reader
(HTIII; Anthos Labtec Instruments, Salzburg, Austria) at
450-nm. All samples were measured as duplicates and the
mean was calculated for data analysis. A negative control
was run for each test as a blank well without plasma
probes.
Statistical analyses
Medians and ranges were calculated for all markers. Non-
parametric statistical calculations were performed
throughout this study. The Mann-Whitney-U-test for
unpaired samples, the Kruskal-Wallis-test for multiple
comparisons, and the rank correlation coefficient accord-
ing to Spearman were used (SPSS 13.01 for Windows,
SPSS Inc. Chicago, IL; GraphPad Prism 4.0, GraphPad
Software Inc., San Diego, CA). Statistical differences of at
least p < 0.05 (two-sided) were considered statistically sig-
nificant.
ROC analyzes were performed with the program Med-
Calc, version 8.2.0.1 (MedCalc Software, Mariakerke, Bel-
gium) and with the mROC program, version 1 for
combining tumour markers [29]. Because of multiple
inferences obtained by ROC analyzes, the p-values were
adjusted by the sequentially rejective Bonferroni test [30].
Results
Plasma concentrations of MMP1, MMP2, MMP3, MMP9, 
TIMP1, TIMP2, and MTC1 in TCC of the bladder
In the control group, plasma concentrations of MMP1,
MMP2, MMP3, MMP9, TIMP1, TIMP2, and MTC1 are not
correlated to age (rs = -0.196 to 0.109; p > 0.05) and are
not significantly different between female and male con-
trols (Mann-Whitney U-test, p < 0.05). The data were
therefore combined and compared with the results of the
bladder carcinoma patients.
All results of this study are of exploratory nature and are
summarized in Table 1. In the group of patients with non-
metastasized TCC of the bladder only the plasma concen-
tration of MMP2 was significantly higher in comparison
to the controls. The plasma concentrations of TIMP1,
TIMP2, and MTC1 were significantly lower in patients
with TCC compared to the control group (Table 1). A
more detailed analysis showed that all parameters were
not different between patients with superficial (n = 43)
and invasive (n = 14) TCC of the bladder (p = 0.258 –
0.767). Considering the effect of histological grading on
the MMP and TIMP levels, only MMP1 differed between
grade 1 and 2 (median 4.4 vs. 1.9, p = 0.006) while the
concentrations of all parameters were independent of the
histolological grade (p = 0.101 – 0.532). In metastasized
patients, the concentration of MMP2 (p < 0.001) and the
ratio of MMP2 to TIMP1 (p < 0.001) were significantly
elevated compared to the control group. Plasma concen-
trations of MMPs, TIMPs, and MTC1 except for TIMP2
were higher in the group of metastasized tumours com-
pared to the patients of non-metastasized TCC (Table 1).
Correlation of MMPs and their inhibitors between each 
other and to the TNM-classification
Table 2 presents the Spearman's correlation coefficients
among the MMPs, TIMPs, and MTC1 and also the rela-
tionships of the markers to the tumour stage and grade.
TIMP1 in blood plasma correlated not only to tumour
stage and grade (Table 2) but also to the lymph node
involvement (rs = 0.275; p = 0.027). There was a statisti-
cally significant correlation between the MMP2 plasma
concentration and distant metastasis of TCC (rs = 0.259; p
= 0.035). Plasma concentrations of MMP1, MMP3,
MMP9, TIMP2, and MTC1 did not correlate to tumour
stage and grade (Table 2), but also to lymph node involve-
ment or distant metastasis (data not indicated).BMC Urology 2006, 6:19 http://www.biomedcentral.com/1471-2490/6/19
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Diagnostic validity of the single markers and marker 
combinations
ROC curves were generated to analyze the diagnostic val-
ues of the markers (Figures 1, 2). Table 3 presents the areas
under the curve (AUC) as the overall index for the diag-
nostic performance of the respective single markers [31].
MMP2 was the marker with the highest AUC. To use the
information of more than one marker, we also calculated
the diagnostic performance of combinations of markers.
From the practical point of view, we decided to use not
more than three markers in combination. For that pur-
pose, we used the ratio of the two best single markers
(MMP2, TIMP1) and the best combinations with two and
three markers calculated by the mROC program [29]. That
special program calculates the linear combination, which
maximizes the AUC for all markers selected and also for
all two- and three-marker combinations among the
selected markers. The equation for the respective combi-
nation is provided and can be used as a new virtual
marker. The best two-marker combination included
MMP9 and TIMP1, while the best three-marker combina-
tion included MMP2, MMP9, and TIMP1. The ROC curves
of these three combinations and the corresponding AUCs
in comparison to the best single marker MMP2 clearly
show the distinct improvement of diagnostic performance
if marker combinations were used (Table 3, Figures 1 and
2). As shown by the best two-marker combination,
including MMP9 and TIMP1, the optimized combination
does not always include the best single markers (Table 3).
All data were statistically adjusted by applying the sequen-
tially rejective Bonferroni method.
In addition to the overall result of diagnostic performance
defined by the AUCs of the ROC analyzes, the sensitivity
and specificity results of all markers and of the best two-
and three-marker combinations were calculated at certain
cutoffs. The marker concentrations with the highest diag-
nostic accuracy (minimal false-negative and false-positive
results), marked in the ROC curves of Figures 1 and 2,
were selected as cutoff values. Table 4 presents the diag-
nostic sensitivity and specificity of the MMPs and TIMPs
to distinguish between healthy persons and bladder can-
cer patients. We included the cutoffs at the 95% limits of
sensitivity and specificity and calculated the correspond-
ing specificity and sensitivity values (Table 4). The
improved sensitivity and specificity values are obvious if
the two- and three-marker combinations calculated by the
mROC program were used [29]. Both sensitivity and spe-
cificity increased to over 90% with the three-marker com-
bination MMP2, MMP9, and TIMP1 (Table 4, Figure 2).
These results could be confirmed by subsequent calcula-
tions with splitted data using 2/3 of samples for the calcu-
Table 1: Plasma concentrations of MMP1, MMP2, MMP3, MMP9, TIMP1, TIMP2, the MMP1/TIMP1-complex (MTC1), and the ratio of 
MMP2/TIMP1 of healthy volunteers, of patients with non-metastasized (BCa) and metastasized (mBCa) TCC of the bladder.
Controls (n = 79) BCa (n = 57) mBCa (n = 11)
MMP1 (μg/l) 5.6 (0.6–24.4) 2.8 (0.6–20.6)
*p < 0.001
4.4 (0.6–24.4)
*p > 0.05
+p > 0.05
MMP2 (μg/l) 749 (547–1295) 1030 (406–3751)
*p < 0.001
1114 (820–2182)
*p < 0.001
+p > 0.05
MMP3 (μg/l) 11.9 (0.18–34.9) 9.9 (0.3–37.4)
*p > 0.05
17.7 (0.6–27.9)
*p > 0.05
+p > 0.05
MMP9 (μg/l) 19.4 (3.52–411) 22.9 (4.4–412)
*p > 0.05
56.3 (6.1–269)
*p > 0.05
+p > 0.05
TIMP1 (μg/l) 423 (121–1776) 184 (57.8–1084)
*p < 0.001
300 (207–1029)
*p > 0.05
+p > 0.05
TIMP2 (μg/l) 146 (91–374) 132 (24.9–424)
*p < 0.01
128 (76.0–335)
*p > 0.05
+p > 0.05
MTC1 (μg/l) 30.5 (4.1–143) 24.8 (2.8–63.3)
*p > 0.05
30.3 (15.1–74.3)
*p > 0.05
+p > 0.05
Ratio of MMP2/TIMP1 1.87 (0.47–7.37) 5.83 (0.87–23.3)
*p < 0.05
3.07 (1.02–9.56)
*p < 0.001
+p > 0.05
Key: TCC = transitional cell carcinoma of the bladder; MMP = matrix metalloproteinase; TIMP = tissue inhibitor of matrix metalloproteinase; 
MTC1 = MMP1/TIMP1-complex. Values are presented as median values with ranges (in parentheses). Statistical differences among the groups were 
calculated by the non-parametric Kruskal-Wallis test. Statistical significances of at least p < 0.05 are typed in 'bold'; comparisons are indicated by 
following symbols: *, between controls and BCa, as well as mBCa; +, between BCa and mBCa.BMC Urology 2006, 6:19 http://www.biomedcentral.com/1471-2490/6/19
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lation of the equations for the marker combinations by
the mROC program and 1/3 of data as test samples (data
not shown). For better visualization dot blots are shown
for the best single marker MMP2 in combination with the
marker combinations obtained by the mROC program
with the highest sensitivities and specificities (Figure 3).
The positivity rates of the markers were additionally ana-
lyzed in the different groups of carcinoma patients. Based
on the cutoff values given in Table 4, test results were clas-
sified as either negative or positive. These dichotomous
variables were analyzed using the chi-square test for the
association of sensitivity in relation to stage and grade cat-
egories, non-metastasized and metastasized bladder can-
cer. Plasma concentrations of MMP1, MMP3, MMP9,
TIMP2, and the MTC1 did not correlate to tumour stage,
grade, lymph node involvement, or distant metastasis.
Only the sensitivity of TIMP1 was associated with the
tumour grading (Chi-square, p = 0.038) as we expected
from the results as presented in Table 2.
Discussion
The value of MMPs and TIMPs expression in bladder tissue
Despite the clinical significance on the pathogenetic
impact of MMPs in human bladder cancer only a limited
number of studies are available in the literature. MMP2,
MMP9, and TIMP2 are the most frequently investigated
metalloproteinases and inhibitors in human bladder tis-
sue [4,32-34]. It has been described in the literature that
elevated expressions of MMP2 and MMP9 in bladder can-
cer tissue at the mRNA and protein level are associated
with advanced tumour stage, grade, and a decreased sur-
vival rate [32-34]. Kanayama et al. [33] found an elevated
mRNA expression of MMP2 and MMP9 in tissue of mus-
cular invasive bladder tumours compared to non-invasive
tumours. The authors concluded that MMP2 and TIMP2
contribute to bladder tumour invasiveness and therefore
might be useful prognostic markers in the future. Overex-
pressions of MMPs are associated with various pathologi-
cal events [35]. Gakiopoulou et al. [36] found that TIMP2
is involved in regulation of apoptosis and is associated
Table 3: Areas under the ROC curves (AUC) for MMPs and TIMPs as single markers and for marker combinations in comparison to 
MMP2 as the single marker with the highest AUCa.
Variables AUCa  P valuesb
(95% confidence interval) Comparison with AUC 0.5 Pairwise AUC comparison with the 
AUC for MMP2
MMP1 0.72 (0.64 – 0.80) <0.001 0.249
MMP2 0.82 (0.74 – 0.88) <0.001
MMP3 0.54 (0.45 – 0.63) <0.443 <0.001
MMP9 0.62 (0.53 – 0.70) <0.054 <0.001
TIMP1 0.78 (0.70 – 0.84) <0.001 0.443
TIMP2 0.65 (0.56 – 0.73) 0.004 0.005
MTC1 0.61 (0.52 – 0.69) 0.086 0.005
Ratio of MMP2/TIMP1 0.87 (0.79 – 0.92) <0.0001 0.254
MMP9 + TIMP1c (mROC combination) 0.96 (0.91 – 0.99) <0.001 <0.001
MMP9 + TIMP1 + MMP2c (mROC combination) 0.99 (0.95 – 1.00) <0.001 <0.001
aAUCs were calculated with all bladder carcinoma patients and healthy controls.
bP values were adjusted according to the sequential Bonferroni correction [29].
cThe equations for the marker combinations calculated by the mROC program were Z = 0.0204 MMP9 - 0.00415 TIMP1 for the best two marker 
combination, and Z = 0.00159 MMP2 + 0.0227 MMP9 - 0.00446 TIMP1 for the best three marker combination, respectively. Using these equations 
a new virtual marker was calculated.
Table 2: Correlation coefficients according to Spearman between MMPs, TIMPs, and to stage and grade for all patients suffering from 
bladder cancer and healthy controls.
MMP1 MMP2 MMP3 MMP9 TIMP1 TIMP2 MTC1
T-Stage 0.05 0.15 0.16 0.10 0.32* 0.05 0.12
Grading -0.10 0.14 0.07 0.12 0.29* 0.01 0.11
MMP1 1.00 -0.30* 0.08 0.16 0.44* 0.10 0.47*
MMP2 1.00 0.11 -0.06 -0.26* 0.13 0.02
MMP3 1.00 0.01 0.16 0.08 0.09
MMP9 1.00 0.61* 0.14 0.081
TIMP1 1.00 0.33* 0.26*
TIMP2 1.00 0.06
MTC1 1.00
*Significances of at least p <0.05.BMC Urology 2006, 6:19 http://www.biomedcentral.com/1471-2490/6/19
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A-H. ROC curves for MMP1, MMP2, MMP3, MMP9, TIMP1, TIMP2, MMP1/TIMP1-complex, and the ratio of MMP2 to TIMP1  from bladder cancer patients Figure 1
A-H. ROC curves for MMP1, MMP2, MMP3, MMP9, TIMP1, TIMP2, MMP1/TIMP1-complex, and the ratio of MMP2 to TIMP1 
from bladder cancer patients. The healthy controls are included. AUCs are given in Table 2. MMP2 showed the largest, MMP3 
the highest AUC. The cutoff point (black square box) in each curve indicates the point with the highest diagnostic accuracy.BMC Urology 2006, 6:19 http://www.biomedcentral.com/1471-2490/6/19
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with an adverse prognosis in patients with TCC of the
bladder. One group investigated MMP1 and MMP3 pro-
tein expression by immunohistochemistry [15]. They
showed a correlation for MMP1 expression and tumour
aggressiveness, but no detectable expression for MMP3.
Vasala et al. [4] demonstrated an overexpression of MMP2
immunohistochemically. MMP2 overexpression corre-
lated with bladder cancer stage, but not with grade. The 5-
year survival rate for patients with bladder cancer was sig-
nificantly lower in the MMP2 positive group.
In the most recent study on MMPs and their inhibitors
urothelial carcinoma specimens were profiled for 24
MMPs and the four endogenous tissue inhibitors and
their receptors using quantitative real time RT-PCR [37].
This study showed that MMP2, MT1-MMP, and MMP28
were very highly expressed in bladder tumour samples
and MMP1, 7, 9, 11, 15, 19, and 23 were also highly
expressed. TIMP1 and TIMP3 correlated with an increas-
ing tumour grade. By laser capture microdissection of
RNA it was possible to locate the MMP expression within
the tissue. The study revealed that the most highly
expressed MMPs are located in the stroma, except
MMP13, which was located in the epithelium. Wallard et
al. [37] confirmed in their study the impact of MMP1,
MMP2, MMP9, and TIMP1 as potential diagnostic and
therapeutic targets and supported the impact of those
MMPs and TIMP1 as clinical markers for bladder cancer.
In neoplastic diseases an imbalance of MMPs and TIMPs,
leading to an excess of degradative activity, is supposed to
be linked to the invasive character of tumour cells [12,13].
Their proteolytic activity is activated by a complex cas-
cade, which is not yet completely understood. Activated
MMP1, MMP3 and latent forms of MMP2 and MMP9 are
regulated and inhibited by endogenous proteins known
as tissue inhibitors of metalloproteinase TIMP1 and
TIMP2 [17]. Studies have shown that TIMP1 binds prefer-
ably to MMP9 and TIMP2 preferably to MMP2 [18].
Kugler et al. [38] stated for renal cell carcinoma (RCC)
that the balance of MMP2- and MMP9- to TIMP1- and
TIMP2-mRNA expression is a prognostic factor of tumour
aggressiveness. Increased expression of TIMP1 in RCC cor-
relates with poor prognostic variable including shortened
patient survival. The paradoxical poor prognostic implica-
tion of TIMP overexpression documented in the literature
complements the dual function of TIMPs and warrants
further investigation [39].
Diagnostic values of MMPs, TIMPs and their combination 
tested in blood plasma
There are only limited data available on circulating MMPs
and TIMPs in patients with bladder cancer. Gohji et al.
[40] analyzed MMP2 and MMP3 concentrations in blood
serum of patients with bladder cancer. They found ele-
vated concentrations of MMP2 and MMP3 in patients
with advanced TCC of the bladder (pT2-T4, N+, M+) in
comparison to the serum of patients with superficial
tumors (Ta-T1, N0, M0). Their studies revealed further
elevated MMP2, MMP3, and TIMP2 concentrations from
patients after tumour resection, which might function as a
predictive value for early detection of tumour recurrence
[20,40]. Further, Guan et al. [16] correlated MMP9 expres-
sion in the serum to tumour grade and stage as a clinical
prognostic factor. However, it has been shown that all
MMP measurements in serum give equivocal values [23].
To our knowledge, there is no publication so far available
on detection of MMPs and TIMPs in blood plasma for
bladder cancer detection. On the basis of the concept that
MMPs are synthesized in tissue and released into the
blood stream we evaluated the levels of MMPs, their
inhibitors, and MTC1 in blood plasma from patients with
TCC of the bladder at different grades, stages, and with
and without metastasis. Although citrate was recently sug-
gested to be the most suitable anticoagulant to prepare
blood samples for MMP measurements [41], comparable
MMP activities in heparin and citrate plasma samples
were found [42]. The plasma concentration of MMP2 was
significantly higher in comparison to the control group
ROC curves for the best two-marker and three-marker  combination calculated by the mROC program Figure 2
ROC curves for the best two-marker and three-marker 
combination calculated by the mROC program. The red line 
presents the ROC curve for the linear combination of MMP9 
and TIMP1, the blue one the curve with the marker combina-
tion of MMP2, TIMP1, and MMP9. The equations of these vir-
tual markers are given in Table 3.BMC Urology 2006, 6:19 http://www.biomedcentral.com/1471-2490/6/19
Page 8 of 12
(page number not for citation purposes)
whereas the concentrations of MMP1, TIMP1, TIMP2, and
MTC1 were significantly lower from patients with non-
metastasized TCC of the bladder in comparison to the
healthy control group (Table I). In comparison to the
expression data in tissue described above, these results
confirm that circulating MMPs and TIMPs do not always
reflect the direct tissue situation. That phenomenon, well
known in clinical enzymology as enzyme distortion, has
also to be considered for MMPs and TIMPs [43]. Since the
mechanisms of release into extracellular space, the distri-
bution in the intravascular compartment, and the elimi-
nation from that compartment can differently affect these
analytes. Both changes of quantitative and qualitative
relations between them are possible. For the complex
interconnections between the various MMP components
and pathways in tissue, Overall and Kleifeld [44] recently
introduced the term "protease web" and underlined that
the interactions between MMPs, TIMPs, and related com-
ponents are more important than the single components.
We believe that this complexity may essentially determine
the distortion between tissue expression and blood pat-
tern of MMPs and TIMPs. That aspect makes it also under-
standable that the levels of MMPs and TIMPs in plasma
have a limited value to attribute these values to their
expression in tissue and vice versa. Another important
aspect is the fact that we only measured non-active MMPs.
However, it is well known that, for example, the ratios of
active to total MMP2 and MMP9, respectively are changed
in tumour tissue and also in plasma [45,46].
Plasma concentrations from patients with metastasized
tumours showed statistically significant higher values for
TIMP1 compared to samples from non-metastasized
tumours. That phenomenon could be a result of the dual
function of the TIMP1 as already discussed in the previous
chapter. Due to the possible pre-analytical interferences
mentioned above it is not possible to compare our data
measured in plasma to the data from investigations in
serum. In this study the diagnostic performance criteria
sensitivity, specificity, and ROC data revealed the best val-
ues for MMP2 as a separate tumour marker for TCC. Com-
paring our data on different MMPs MMP2 was proved to
be the best marker alone. It was statistical significantly ele-
vated in superficially, invasive bladder tumours and in
metastasized bladder tumours in comparison to the
healthy control group (p < 0.001) (Table 1). MMP2 was
also shown to stand alone as clinical tissue marker in
other studies as described above.
Using the statistical mROC program we have calculated
the different sensitivities and specificities for all MMPs
and TIMPs at their different cutoff points (Figures 1, 2 and
Table 4) and additionally determined the best combina-
tion of two and three markers (Table 4, Figure 3). The best
single indicators with the highest sensitivity and specifi-
city (MMP2, TIMP1) did not necessarily reached the high-
est sensitivities and specificities in combination with the
next best indicators. However, MMP2 does not reach a sat-
isfying sensitivity when tested alone. At the cutoff point it
reaches only 75% sensitivity and specificity than when
tested in combination with MMP9 and TIMP1 (97% sen-
sitivity, 94% specificity). Our results show that different
indicators in specific combinations could result in an
improved sensitivity and specificity in comparison to the
Table 4: Diagnostic sensitivities and specificities of MMPs, TIMPs, 
and the MMP1/TIMP1-complex (MTC1) as single markers and 
two- and three-marker combinations to distinguish between 
healthy persons and bladder cancer patients at the 95% limits of 
sensitivity and specificity, respectively.a
Marker (μg/l) Sensitivity (%)b Specificity (%)
Single marker
MMP1
16.5 95 (85 – 98) 4.2 (1 – 12)
0.95 24 (15 – 34) 95 (85 – 98)
MMP2
613 95 (85 – 98) 7 (2 – 15)
1071 47 (35 – 60) 95 (85 – 98)
MMP3
25.2 95 (85 – 98) 3 (0.4 – 10)
3.1 13 (6 – 24) 95 (85 – 98)
MMP9
6.0 95 (85 – 98) 20 (11 – 31)
106 12 (5 – 22) 95 (85 – 98)
TIMP1
655 95 (85 – 98) 26 (16 – 38)
158 38 (27 – 51) 95 (85 – 98)
TIMP2
315 95 (85 – 98) 1.4 (0.2 – 7.4)
112 40 (28 – 52) 95 (85 – 98)
MTC1
57.3 95 (85 – 98) 12 (6 – 22)
6.9 6 (2 – 15) 95 (85 – 98)
Marker combinationsc
Ratio of MMP2 to TIMP1
1.65 95 (85 – 98) 46 (34 – 58)
5.45 49 (36 – 61) 95 (85 – 98)
mROC combinationsd
MMP9 + TIMP1
-1.004 95 (85 – 98) 74 (62 – 84)
-0.482 82 (70 – 90) 95 (85 – 98)
MMP9 + TIMP1 + MMP2
0.745 95 (85 – 98) 94 (85 – 98)
0.841 94 (85 – 98) 95 (85 – 98)
aData results from ROC analysis (see Figures 1, 2) performed with 
the 79 controls and 68 patients with bladder cancer. The cutoffs 
correspond to the values at 95% sensitivity and specificity as indicated.
b95% confidence intervals are given in parentheses.
cAs marker combinations the ratio of the two best single markers 
(MMP2, TIMP1) and the best combinations based on the highest 
AUCs with two and three markers calculated by the mROC program 
(see Table 2; further details see text) were selected.
dThe equations for the marker combinations used for the calculation 
of the respective new virtual marker is given in the legend of Table 3.BMC Urology 2006, 6:19 http://www.biomedcentral.com/1471-2490/6/19
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Dot-plots for presentation of the best marker combinations to distinguish between healthy persons (black dots) and bladder  cancer patients (open dots) Figure 3
Dot-plots for presentation of the best marker combinations to distinguish between healthy persons (black dots) and bladder 
cancer patients (open dots). A: Ratio of MMP2 to TIMP1 versus MMP2; B: mROC combination of MMP9+TIMP1 versus MMP2; 
C: mROC combination of MMP2+MMP9+TIMP1 versus MMP2. The dashed lines indicate the cutoff values for 95% sensitivity 
of MMP2 and the corresponding marker combinations.BMC Urology 2006, 6:19 http://www.biomedcentral.com/1471-2490/6/19
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best single indicator test by itself, which has never been
shown so far in the literature (Table 3, 4, Figure 2). We
presented in this study that single markers have only a
limited diagnostic value. Separate analyzes of MMP1,
MMP2, MMP3, MMP9, TIMP1, TIMP2, and MTC1 in
plasma do not allow a prognostic prediction for tumour
grading, staging, or metastasis, but certain combinations
could be very helpful. Although the limitations of our
study should be considered that the results are based on a
small number of patients and patients of benign urologi-
cal diseases (inflammations) were not included. We sug-
gest specific MMPs and their combinations as potential
helpful diagnostic indicators in early and advanced blad-
der cancer. To some degree there might exist an overfitting
in the resulting data of the two virtual mROC classifiers
because MMP9 and TIMP1 in the two best combinations
are the markers with the highest correlation to each other.
There are controversial opinions in the literature. How-
ever, we used a similar approach as Piironen et al. [47],
who included covariates of a correlation coefficient <0.7
into a common multivariate model. Further prospective
studies should prove the usefulness of these marker com-
binations. However, so far it is not economic efficient and
not practical to combine those three markers for routine
tumour screening. Further investigations are still neces-
sary for easier analyzes of MMPs and TIMPs and a more
economical application to the clinical routine.
Conclusion
Improved detection methods for diagnosis of asympto-
matic bladder cancer are essential for an early and reliable
diagnosis and a curative treatment of this tumour entity.
The standard diagnostic is still the cystoscopy with biopsy
of suspicious bladder tissue, which is, however, invasive.
Several research projects focus on finding tumour mark-
ers, which are easy and inexpensive to obtain, for example
in urine and blood, for a non-invasive way of bladder can-
cer detection.
The values of MMPs and TIMPs as potential diagnostic
tumour markers in bladder cancer have been discussed in
the literature. In earlier studies expression changes of
MMPs and their inhibitors have been detected in tumour
tissue and in blood serum. But for the first time we could
evaluate that MMP2 as a statistically significant marker in
blood plasma for bladder cancer detection with an
increased diagnostic value in combination with MMP9
and TIMP1. We found that the markers with the highest
diagnostic values do not reach the sensitivity and specifi-
city like other markers would show in a combination. The
clinical value of separately used MMPs and TIMPs as
tumour markers in blood plasma is limited. On the basis
of these observations we conclude that measurements of
plasma MMP and TIMP levels in relevant combinations
may provide important data for selecting patients for
treatment with drugs that interfere with MMP and TIMP
activities.
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